A5033513176- Heart Failure Treatment and Management
- Bone health and osteoporosis research
- Osteoarthritis Treatment and Mechanisms
- Potassium and Related Disorders
- Bone health and treatments
- Bipolar Disorder and Treatment
- Parathyroid Disorders and Treatments
- Hormonal Regulation and Hypertension
- Antimicrobial Peptides and Activities
- Cell Adhesion Molecules Research
- Cardiovascular Function and Risk Factors
- Electrolyte and hormonal disorders
- Cancer-related gene regulation
- Blood Pressure and Hypertension Studies
- Diabetes Treatment and Management
- Renal and Vascular Pathologies
- Bone and Joint Diseases
- Acute Ischemic Stroke Management
- Cardiac Valve Diseases and Treatments
- Coronary Interventions and Diagnostics
- Dialysis and Renal Disease Management
- Venous Thromboembolism Diagnosis and Management
- Mercury impact and mitigation studies
- Cancer-related molecular mechanisms research
- Pharmacological Effects and Toxicity Studies
Icahn School of Medicine at Mount Sinai
2021-2024
Mount Sinai Hospital
2021-2024
New York Hospital Queens
2023
NewYork–Presbyterian Hospital
2023
The Rogosin Institute
2023
Hospital for Special Surgery
2011-2016
Cornell University
2011
Secondary hyperparathyroidism is associated with osteoporosis and fractures. Etelcalcetide an intravenous calcimimetic for the control of in patients on hemodialysis. Effects etelcalcetide skeleton are unknown.
We showed previously that E74-like factor 3 (ELF3) protein levels are increased in osteoarthritic (OA) cartilage, ELF3 accounts for inflammatory cytokine-driven MMP13 gene expression, and that, upon induction by interleukin-1β, binds to the COL2A1 promoter suppresses its activity chondrocytes. Here, we aimed further investigate mechanism/s which represses transcription chondrocytes.We report inhibits Sox9-driven interfering with activator functions of CBP/300 Sox9. Co-transfection...